TP53 and colorectal carcinoma: Notably, more advanced CRC showed higher TP53 variation and p53 aberrant expression rates (66.4% in stage I and II vs. 80.9% in stage III and IV and 66.4% in stages I and II vs. 83% in stages III and IV, respectively) [34].